The treatment of mice with the non-selective Panx1 blocker Probenecid reduced ATP release and slowed renal cyst development by improving epithelial transport across the cyst epithelium, thus demonstrating that Panx1 could be a new target for the treatment of ADPKD [14]. Here, PANX1 is linked to cystic kidney disease.